Erika Rubesova, MD

• Clinical Assistant Professor of Radiology
• Lucile Packard Children's Hospital
• Stanford, California

Amphotericin B lipid complex in the management of invasive fungal infections in immunocompromised patients midfoot arthritis order genuine mobic line. Amphotericin B membrane action: role for two types of ion channels in eliciting cell survival and lethal effects arthritis in dogs when to euthanize order discount mobic online. Bench-to-bedside review: therapeutic management of invasive candidiasis in the intensive care unit arthritis in base of neck discount mobic 15 mg free shipping. Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents arthritis diet suggestions buy mobic 15 mg visa. Kinetic suppression of microtubule dynamic instability by griseofulvin: implications for its possible use in the treatment of cancer arthritis pain while pregnant order mobic uk. Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections. Caspofungin for prophylaxis and treatment of fungal infections in adolescents and adults: a meta-analysis of randomized controlled trials. Efficacy of topical antifungals in the treatment of dermatophytosis: a mixedtreatment comparison meta-analysis involving 14 treatments. Chemotherapy of protozoal infections: amebiasis, giardiasis, trichomoniasis, trypanosomiasis, leishmaniasis, and other protozoal infections. Visceral leishmaniasis: host-parasite interactions and clinical presentation in the immunocompetent and in the immunocompromised host. From methylene blue to chloroquine: a brief review of the development of an antimalarial therapy. Chemotherapeutic strategies for reducing transmission of Plasmodium vivax malaria. Current status of the clinical development and implementation of paediatric artemisinin combination therapies in Sub-Saharan Africa. A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy. Analysis of current antifungal agents and their targets within the Pneumocystis carinii genome. Current and future perspectives on the chemotherapy of the parasitic protozoa Trichomonas vaginalis and Entamoeba histolytica. Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8aminoquinoline treatment regimens: a workshop report. Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for uncomplicated malaria: a systematic review. Sulfadoxinepyrimethamine resistance in Plasmodium falciparum: a zoomed image at the molecular level within a geographic context. Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis. Quinine, an old antimalarial drug in a modern world: role in the treatment of malaria. Artemisinin and its derivatives: a novel class of anti-malarial and anti-cancer agents. Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria. Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum. Although some types of tumors are well contained (benign), malignant tumors continue to proliferate within local tissues and can possibly spread (metastasize) to other tissues in the body. The term cancer specifically refers to the malignant forms of neoplastic disease, which can often be fatal, as tumors invade and destroy tissues throughout the body. Cancer cells, however, are unique in their progressive invasion of local tissues and their ability to metastasize to other tissues. In addition, cancers associated with the formed blood elements are connoted by the suffix -emia. Many other descriptive terms are used to describe various malignancies, and certain forms of cancer are often named after a specific person. It is beyond the scope of this chapter to describe all the various types of malignancies. You may want to consult a pathology text or similar reference for more information about the location and morphology of particular forms of cancer. Conversely, certain positive lifestyles, including adequate exercise, a high-fiber diet, and the avoidance of tobacco products, may be crucial in preventing certain forms of cancer. Of course, routine checkups and early detection play a vital role in reducing cancer mortality. When cancer is diagnosed, three primary treatment modalities are available: surgery, radiation treatment, and cancer chemotherapy. The purpose of this chapter is to describe the basic rationale of cancer chemotherapy and to provide an overview of the drugs that are currently available to treat specific forms of cancer. For reasons that will become apparent in this chapter, these drugs tend to produce toxic effects that directly influence physical therapy and occupational therapy procedures. Therefore, this chapter should provide you with a better understanding of the pharmacodynamic principles and beneficial effects, as well as the reasons for the potential adverse effects of these important drugs. However, the pharmacological treatment of cancer represents a unique and perplexing problem. Although cancer cells have become more primitive and have lost much of their normal appearance, they are still human cells that have simply gone wild. In addition, they cannot be easily destroyed without also causing some harm to healthy human tissue. The concept of selective toxicity becomes more difficult to achieve when using anticancer drugs in contrast to drugs that attack foreign invaders and parasites, such as antibacterial drugs or antifungal drugs (see Chapters 33 through 35). Most traditional anticancer drugs lack specificity-that is, these drugs impair function in noncancerous tissues as well as in cancerous cells. Cancerous cells have a greater need to replicate their genetic material and thus undergo mitosis at a much higher rate than most noncancerous cells. On the other hand, researchers have been making considerable effort to develop chemotherapeutic agents that somehow target only the cancer cells, thus reducing the toxicity to healthy cells. Examples of cell-cycle­nonspecific agents include most alkylating agents and antineoplastic antibiotics. Cell-cycle­specific drugs will be effective only in cells that are progressing through the cell cycle-that is, cells that are not remaining in the nondividing (G0) phase. Cell-cycle­nonspecific agents have a more general effect and should inhibit replication in all the cells that the drug reaches. Concepts of Growth Fraction and Cell Kill Cancer cells are not all uniform in their rate of replication and proliferation. In any given tumor or type of disseminated cancer, certain cells do not proliferate, while other cells reproduce at variable rates. The term growth fraction refers to the percentage of proliferating cells relative to total neoplastic cell population. Fortunately, these are the cells that must be killed to prevent the cancer from spreading. In addition, the growth fraction typically decreases as a tumor gets larger-that is, the percentage of cells that are actively dividing starts to decline as the tumor gets larger because blood flow and nutrient supply to the tumor cannot sustain extremely rapid tumor growth. The cell kill hypothesis is based on the idea that each round of chemotherapy will kill a certain percentage of cancerous cells. According to this theory, the chemotherapeutic regimen can never completely eliminate the tumor because some percentage of cells will remain alive after each round of treatment. There is a greater chance of survival if several rounds of chemotherapy are instituted in fairly rapid succession when the tumor is small and a large proportion of the cells are actively dividing. If the first round of chemotherapy kills 90 percent of the cancerous Cell-Cycle­Specific Versus Cell-Cycle­Nonspecific Drugs Antineoplastic drugs are sometimes classified as either cell-cycle specific or cell-cycle nonspecific. For instance, most antimetabolites (cytarabine, methotrexate, others) act when the cell is in the S phase. Examples of cellcycle­specific drugs are listed next to the phase of the cycle they act on. S synthesis) Cell-cycle nonspecific: Alkylating agents Anticancer antibiotics Dacarbazine cells, 1 million cells will survive. A second round will kill 90 percent of the remaining cells, leaving 100,000 cells, and a third round will kill 90 percent of those cells, leaving 10,000 cancerous cells. Prevalence and Management of Adverse Effects Because antineoplastic agents often impair replication of normal tissues, these drugs are generally associated with several common and relatively severe adverse effects. Normal human cells must often undergo controlled mitosis to sustain normal function. The cancer cells, however, tend to suffer these toxic effects to a greater extent because of their increased rate of replication and cell division. Still, healthy cells often exhibit some toxic effects, even at the minimum effective doses of the chemotherapeutic agents. Considering that cancer is usually life-threatening, these toxic effects must be expected and tolerated during chemotherapeutic treatments. Analgesics (see Chapters 14 and 15) are often needed to help patients cope with cancer pain and to make the rigors of chemotherapy treatment more tolerable. The primary groups of antineoplastic drugs are the alkylating agents, antimetabolites, anticancer antibiotics, antimicrotubule agents, topoisomerase inhibitors, antineoplastic hormones, targeted/biological therapies, platinum coordination complexes, and several other miscellaneous drug groups and individual agents. The cell therefore cannot synthesize vital cellular proteins (enzymes, transport proteins, etc. As indicated, these agents represent one of the largest categories of anticancer drugs and are used to treat a variety of leukemias, carcinomas, and other neoplasms. These drugs are therefore called antimetabolites because they interfere with the normal metabolites during cellular biosynthesis. This effect would be like baking a cake but substituting an inappropriate ingredient (salt) for a normal ingredient (sugar). These enzymes do not recognize the difference between the antimetabolite drug and the normal metabolite and waste their time trying to convert the antimetabolite into a normal metabolic product. The enzyme, however, cannot effectively act on the drug, so the normal metabolic products are not formed. The exact mechanism of action for these antibiotics to exert antineoplastic effects is still being investigated. Regardless of their exact mechanism, these agents play a role in the treatment of several neoplastic diseases. Likewise, the mitotic apparatus contains certain microtubules that are important in guiding the mitotic apparatus and allowing this apparatus to orchestrate cell division. Hence, several anticancer drugs are available that bind to these microtubules and alter the function of the mitotic apparatus (Table 36-4). In fact, when the cell attempts to divide, the nuclear material becomes disrupted and dispersed throughout the cytosol. This effect causes direct damage to the chromosomes, leading to subsequent cell dysfunction and death. Cancer chemotherapeutic agents that act as antimetabolites and the principal neoplastic diseases for which they are indicated are listed in Table 36-2. As with most anticancer drugs, these agents are especially toxic to cells that have a large growth fraction and undergo extensive replication. These cells have a great need to synthesize nucleic acids-hence the preferential effect of antimetabolites on these cells. Topoisomerase Inhibitors Drugs classified as topoisomerase inhibitors include etoposide, irinotecan, teniposide, and topotecan (Table 36-5). Hence, drugs that either mimic or block (antagonize) the effects of these hormones may be useful in treating certain hormone-sensitive forms of cancer. The primary drugs that inhibit neoplasms via hormonal mechanisms are listed in Table 36-6. In some cases, these drugs work by direct inhibitory effects on cancerous cells. In particular, androgen receptor blockers (flutamide, others) can treat prostate cancer by blocking the effects of testosterone on the prostate gland. Refer to Chapter 30 for more details about the effects of androgens, estrogens, and their respective receptor-blocking agents. Targeted and biological therapies offer the potential advantage of impairing function in the cancer cells with minimal effects on healthy human cells. These therapies include the monoclonal antibodies, cytokines (interferons, interleuklin-2), and tyrosine kinase inhibitors (Table 36-7). Monoclonal Antibodies Monoclonal antibodies are one of the primary ways to target specific cancer cells. When administered, the monoclonal antibody is attracted directly to the cancer cell, without any appreciable effect on healthy tissues-that is, healthy cells lack the antigen that is present on the cancerous cell and should therefore remain unaffected by the drug. New antibodies that selectively inhibit or kill cancer cells with minimal or no effects on healthy tissues will undoubtedly be available in the future. Other strategies to prevent angiogenesis are currently being developed, and various types of angiogenesis inhibitors may be forthcoming. Their role as potential biological anticancer drugs is based on their ability to stimulate the immune mechanisms that normally deal with abnormal cell proliferation. These peptide compounds exert several beneficial effects, including antiviral and antineoplastic activity. However, the exact mechanism of action for interferons to impair cancerous cell growth is not clear. It is possible that interferons affect several aspects of tumor growth, including the activation of cytotoxic immune cells (natural killer cells) and the activation of signaling pathways in the cancer cell that help retard cell division and bring about programmed death (apoptosis) of cancerous tissues. Research continues to identify the antineoplastic role of interleukins, interferons, and other cytokines, as well as to define how these agents can be used alone or in combination to treat various forms of cancer. In certain types of cancer, defective function of tyrosine kinases leads to abnormal cell function and proliferation. These drugs are gaining acceptance as a part of the treatment of certain leukemias, as well as cancers affecting other tissues such as the lungs, stomach, and pancreas.

Insulin also plays a role in protein and lipid metabolism and is important in several aspects of growth and development arthritis in feet pictures order mobic 15 mg with visa. Problems with the production and function of insulin cause a fairly common and clinically significant disease known as diabetes mellitus arthritis in dogs hocks discount 7.5 mg mobic with amex. The bulk of the gland consists of acinar cells that synthesize and release pancreatic digestive enzymes (thereby providing the exocrine function) arthritis pain behind knee purchase generic mobic online. Interspersed within the acinar tissues are smaller clumps of tissue known as the islets of Langerhans can arthritis in the knee be cured order cheap mobic. These islets contain cells that synthesize and secrete pancreatic hormones arthritis diet management generic mobic 7.5 mg otc, thus constituting the endocrine portion of the gland. The pancreatic islets consist of at least five primary cell types: alpha (A) cells, which produce glucagon; beta (B) cells, which produce insulin; delta (D) cells, which produce somatostatin; (F) cells, which produce pancreatic polypeptide; and epsilon (E) cells, which produce ghrelin. The exact physiological roles of the other pancreatic hormones are not entirely clear. Effects of Insulin on Protein and Lipid Metabolism Although insulin is normally associated with regulating blood glucose, this hormone also exerts significant effects on proteins and lipids. In general, insulin promotes storage of protein and lipid in muscle and adipose tissue, respectively. In fat cells, insulin stimulates the synthesis of fatty acids and triglycerides (the primary form of lipid storage in the body), increases the uptake of triglycerides from the blood into adipose and muscle tissues, and inhibits the enzyme that breaks down stored lipids. The primary effect of insulin is to lower blood glucose levels by facilitating the entry of glucose into peripheral tissues. Effects of Insulin on Carbohydrate Metabolism Following a meal, blood glucose sharply increases. Insulin is responsible for facilitating the movement of glucose out of the bloodstream and into the liver and other tissues, where it can be stored for future needs. Insulin appears to directly stimulate this facilitated diffusion, resulting in a tenfold or greater increase in the rate of glucose influx. Hepatic cells are relatively permeable to glucose, and glucose enters these cells quite easily, even when insulin is not present. Glucose, however, is also free to leave liver cells just as easily, unless it is trapped in the cells in some manner. Insulin stimulates the activity of the glucokinase enzyme, which phosphorylates glucose and subsequently traps the glucose molecule in the hepatic cell. Insulin also increases the activity of enzymes that promote glycogen synthesis and inhibits the enzymes that promote glycogen breakdown. Thus, the primary effect of insulin on the liver is to promote the sequestration of the glucose molecule and to increase the storage of glucose in the form of hepatic glycogen. Cellular Mechanism of Insulin Action Insulin exerts its effects first by binding to a receptor located on the surface membrane of target cells. The beta subunit appears to be an enzyme that functions as a tyrosine kinase, which means that it catalyzes the addition of phosphate groups to tyrosine residues within the beta subunit. This autophosphorylation of the insulin receptor then initiates a series of biochemical changes within the cell. The way that the insulin-receptor interaction triggers subsequent changes in cellular activity has been the subject of extensive research. These glucose transporters are proteins that are synthesized and stored within the Golgi system of the cell. Consequently, we now have a fairly clear idea of how insulin binds to a specific receptor and exerts its effects on target cells. The possible role of these receptor-mediated problems in diabetes is discussed later in "Type 2 Diabetes. This gluconeogenesis sustains blood glucose levels even after hepatic glycogen has been depleted. Chronic elevations in blood glucose (hyperglycemia) have been implicated in producing pathological changes in neural and vascular structures. Consequently, insulin and glucagon play vital roles in controlling glucose levels, and the release of these hormones must be closely regulated. The level of glucose in the bloodstream is the primary factor affecting pancreatic hormone release. Insulin then promotes the movement of glucose out of the bloodstream and into various tissues, thus reducing plasma glucose back to normal levels. Glucagon resolves this hypoglycemia by stimulating the synthesis and release of glucose from the liver. The release of insulin and glucagon may also be governed by other energy substrates. Cells located in the pancreatic islets act as glucose sensors, directly monitoring plasma glucose levels in the blood reaching the pancreas. In particular, the beta cells or insulin-secreting cells act as the primary glucose sensors, and adequate control of insulin release seems to be a somewhat higher priority than the control of glucagon function. When insulin release diminishes, the inhibition of glucagon production is removed, and glucagon secretion is free to increase. This intra-islet regulation between insulin and glucagon is important during normal physiological function as well as in pathological conditions, such as the deficiency of insulin production characteristic of type 1 diabetes mellitus. If the endocrine portion of the pancreas is functioning normally, blood glucose levels remain remarkably constant, even in situations such as exercise and prolonged fasting. However, any abnormalities in pancreatic endocrine function can alter the regulation of blood glucose. In particular, problems associated with the production and effects of insulin can produce serious disturbances in glucose metabolism and several other metabolic problems. The pathogenesis and treatment of this disease are presented in the following section. This disease is characterized by a primary defect in the metabolism of carbohydrates and other energy substrates. These metabolic defects can lead to serious acute and chronic pathological changes. The term diabetes mellitus differentiates this disease from an unrelated disorder known as diabetes insipidus. Consequently, the full term diabetes mellitus should be used when referring to the insulin-related disease. It is the leading cause of blindness in adults32 and is responsible for one-third of all cases of end-stage renal disease. There appears to be an almost total destruction of pancreatic beta cells in these individuals. The onset of type 1 diabetes is usually during childhood, so this form of diabetes has also been referred to as juvenile diabetes. Patients with type 1 diabetes are typically close to normal body weight or slightly underweight. The exact cause of type 1 diabetes is unknown, but there is considerable evidence that the beta cell destruction characteristic of this disease may be caused in many patients by an autoimmune reaction. Whereas insulin cannot be produced in type 1 diabetes, the problem in type 2 diabetes is somewhat more complex. The resistance may be caused by a primary (intrinsic) defect at the target cell that results in a decreased response of the cell to insulin. The decreased insulin response most likely occurs because of changes in the way the cell responds after insulin binds to the surface receptor. Problems in postreceptor signaling-such as altered protein phosphorylation, impaired production of chemical mediators, and a lack of glucose transporters-have been suggested as intracellular events that could help explain insulin resistance. Hence, insulin resistance appears to be a complex phenomenon caused by changes in the cellular response to insulin at the tissue level. However, the exact defects in insulin receptor signaling and postreceptor function remain to be determined. As indicated above, a defect in pancreatic beta cell function may also contribute to the manifestations of type 2 diabetes. Moreover, repeated hyperglycemia seems to cause additional damage to beta cells, resulting in a further decrease in beta cell function and response to glucose. Patients with conditions such as hypertension, obesity, and certain hyperlipidemias are also found to have decreased tissue sensitivity to circulating insulin. This results from a relative lack of insulin-mediated glucose uptake and use by peripheral tissues. Hyperglycemia initiates several complex and potentially serious acute metabolic changes. For example, it is usually accompanied by increased glucose excretion by the kidneys (glycosuria). Glycosuria is caused by an inability of the kidneys to adequately reabsorb the excess amount of glucose reaching the nephron. Increased glucose excretion creates an osmotic force that promotes fluid and electrolyte excretion, thus leading to dehydration and electrolyte imbalance. Increased use of fats and protein leads to the formation of acidic ketone bodies in the bloodstream. Perhaps the most devastating complications associated with this disease result from the development of abnormalities in small blood vessels. Maintenance of blood glucose at or close to normal levels-referred to as tight glycemic control-will prevent acute metabolic derangements and greatly reduce the risk of the chronic neurovascular complications associated with this disease. Insulin may also be administered in some cases of type 2 diabetes to complement other drugs (oral antidiabetic agents) and to supplement endogenous insulin release. Insulin Preparations There are many different forms of insulin, depending on the chemical structure and the length of pharmacological effects of each compound (Table 32-2). These sources were obtained by extracting the hormone from the pancreas of the host animal. The animal forms of insulin were effective in controlling glucose metabolism in humans, even though pork insulin has one amino acid that is different from the human insulin sequence, and beef insulin differs from human insulin by 3 amino acids. Certain contemporary forms of insulin are identical to the structure and effects of human insulin. By altering the amino acid sequence slightly, researchers discovered that certain biosynthetic insulins could be absorbed more rapidly than regular human insulin. These intermediate- or long-acting forms provide a sustained background (basal) level of insulin effects throughout the day or night. In addition, pharmacologists have produced biosynthetic longacting insulin glargine and insulin detemir by adding and substituting specific amino acids (glargine) or attaching fatty acids (detemir) to the regular insulin molecule. For instance, a long-acting preparation can provide basal insulin effects, and a rapid-acting agent used around mealtime can provide optimal glycemic control. Finally, several commercial preparations are now available that combine two forms of insulin in the same product. Products that combine two different forms of insulin can help provide optimal control of blood glucose levels while minimizing the number of injections needed to achieve this control. Administration of Insulin Insulin, a large polypeptide, is not suitable for oral administration. Typically, a small syringe or a needle-tipped "pen" that contains a cartridge of a specific type of insulin can be set to inject a given amount of insulin. Patients on long-term insulin therapy are usually trained to administer their own medication. In order to safely use insulin, it is important to provide adequate storage of the preparation, to maintain sterile syringes, to accurately measure the dose and fill the syringe, and to use a proper injection technique. The optimal dosage of insulin varies greatly from patient to patient, as well as within each patient. Factors such as exercise and dietary modification can change the insulin requirements for each individual. However, many patients can make their own insulin adjustments based on periodic blood glucose measurement. Home glucose-monitoring devices permit patients to routinely check their own blood glucose levels. This process of glucose self-monitoring and insulin dosage adjustment permits optimal management of blood glucose levels on a day-to-day basis. Insulin pumps were also developed as a more convenient and precise way to administer insulin. These pumps can deliver a continuous (background) infusion of insulin that can also be supplemented at mealtime by manually activating the pump. These pumps can be worn outside the body, with insulin administered subcutaneously through a small catheter and needle that is held in place by skin tape. These pumps may also provide better control over blood glucose levels while reducing the risk of side effects such as severe hypoglycemia. Currently, the major drawback of insulin pumps is that they can malfunction, primarily because the catheter delivering insulin becomes occluded or obstructed. Nonetheless, insulin pumps currently offer a convenient way to administer insulin, and technological improvements in these devices will continue to improve their safety and reliability. During insulin treatment, insulin is not released exclusively after a meal, as it would be during normal function. Insulin administered from an exogenous source may be present in the bloodstream even if the patient fails to provide glucose by eating. Hence, insulin may reduce blood glucose below normal levels because of the lack of a periodic replenishment of blood glucose from dietary sources. Exercise generally produces an insulinlike effect, meaning that it accelerates the movement of glucose out of the bloodstream and into the peripheral tissues (skeletal muscle) where it is needed. The combined effects of exercise and insulin may produce an exaggerated decrease in blood glucose, thus leading to hypoglycemia. To avoid exercise-induced hypoglycemia, the insulin dose should be decreased proportionally depending on the type, intensity, and duration of the activity. Initial symptoms of hypoglycemia include headache, fatigue, hunger, tachycardia, sweating, anxiety, and confusion.

Purchase mobic 15 mg fast delivery. 2020 Hip Hop Beat Featuring Rod Stewart Prod Mahny Mo & JKeys.

These side effects can be especially problematic when glucocorticoids are used to prevent transplant rejection because these drugs are often given in high dosages for extended periods arthritis in fingers diagnosis purchase 7.5 mg mobic with amex. To lessen the side effects arthritis in neck disability mobic 15 mg purchase with visa, glucocorticoids are typically combined with other nonsteroidal immunosuppressants what does rheumatoid arthritis in fingers look like 15 mg mobic visa, such as cyclosporine arthritis symptoms fingers pictures cheap 15 mg mobic overnight delivery, azathioprine arthritis in fingers nz mobic 7.5 mg purchase mastercard, or immunosuppressive antibodies, so that synergistic effects can be obtained and immunosuppression can be achieved with relatively low doses of each drug. Mycophenolate mofetil (CellCept) is primarily used to prevent or treat organ rejection following cardiac and renal transplantation. This drug is typically combined with other immunosuppressants (cyclosporine, glucocorticoids) to provide optimal immunosuppression in patients receiving these transplant types. The primary adverse effects associated with mycophenolate mofetil are blood disorders. Sulfasalazine (Azulfidine, others) has unique properties, with some antibacterial characteristics similar to sulfonamide drugs (see Chapter 33) and some anti-inflammatory characteristics similar to the salicylates (see Chapter 15). This drug is primarily used to suppress the immune response associated with rheumatoid arthritis and inflammatory bowel disease. The exact mechanism of this drug in immune-related disorders is not fully understood. These drugs were approved originally to treat renal cell cancer but may also be successful in suppressing immune responses. Sirolimus and its analogs are used primarily to prevent organ rejection in people with solid organ transplants (kidney, heart, etc. These drugs also exert several other beneficial effects, including the ability to inhibit smooth muscle proliferation in blood vessel walls. For this reason, sirolimus and everolimus are sometimes incorporated into drug-eluting stents-a supportive tubular structure (stent) is placed in the lumen of a partially occluded artery, and the drug is released slowly from the stent to help reduce vessel occlusion. Sirolimus and its analogs may cause blood lipid disorders, including hypercholesterolemia and hypertriglyceridemia, and may also impair wound healing. Tacrolimus is used primarily to prevent rejection of kidney and liver transplants. This binding provides a somewhat more selective inhibition of immune function than other drugs that exert a general or nonselective inhibition of the immune response. Researchers have also developed antibodies that are very selective for antigens located on the surface of specific T cells and other lymphocytes; these antibodies inhibit cell function or cause destruction of the cell. For example, agents have been developed that block the interleukin-2 receptor, thus preventing interleukin-2 from activating T lymphocytes. Finally, the use of fusion proteins is another strategy for affecting specific immune functions. Antibodies used in rheumatoid arthritis are addressed in more detail in Chapter 16. Fusion proteins basically block the receptor on the T cell that receives the second (co-stimulatory) signal, hence suppressing T-cell activation. Other fusion proteins are in development, and these drugs may provide an effective strategy for modifying immune responses in specific diseases. In summary, immunosuppressant antibodies and fusion proteins continue to gain acceptance as a method for preventing rejection of transplanted tissues and for treating various autoimmune diseases. The pharmacology of these drugs, which are used primarily as anticancer agents, is described in more detail in Chapter 36. Their use as immunosuppressants has generally declined in favor of drugs that have a more selective and strategic effect on immune function. Nonetheless, these drugs may be helpful in certain autoimmune disorders or in preventing the rejection of tissue and organ transplants in specific situations. Nonetheless, thalidomide may help blunt immunological responses by regulating the genes that express tumor necrosis factor-alpha. Likewise, it may be difficult to selectively stimulate certain aspects of the immune system to treat a specific problem without also causing a more widespread and systemic immunologic response. Nonetheless, a few strategies are currently available to modify or stimulate immune function in a limited number of situations. This drug, however, may not be effective in the most common strains of mycobacterium that cause tuberculosis, and its use as a vaccine may also be limited by other side effects. Some evidence suggests that it may activate macrophages locally at the site of the cancer and that these macrophages engulf and destroy tumor cells. When administered directly into the bladder, common side effects include bladder irritation and infection. Systemic administration (immunization) may also cause dermatological reactions. However, there has been considerable interest in developing pharmacological methods to modify or even stimulate immune function in specific situations. Immune globulin (Gamimune, Gammagard, others) is prepared by extracting immunoglobulins from donated human blood. Immune globulin is administered intravenously to boost immune function in several conditions, including primary immunodeficiency syndromes. Commercial preparations of immune globulin mimic the normal role of endogenous immunoglobulins. These preparations therefore directly act as antibodies against infectious agents. They can also help modulate the activity of T lymphocytes, macrophages, and other immune system cells to maintain immune system competence. For example, cytokines such as interferon-alpha and interleukin-2 can be administered to treat certain forms of cancer (see Chapter 36). Likewise, certain interferons can help control viral infections, and interferon-beta may be helpful in autoimmune diseases such as multiple sclerosis (see Chapter 34). Researchers continue to investigate how immune function can be manipulated to treat various diseases, and additional immune system modulators will almost certainly be forthcoming. Finally, vaccines have perhaps been the most significant advancement in modulating immune responses. As addressed in Chapter 34, these agents are typically manufactured by modifying certain antigenic substances, such as a virus, and administering the vaccine prior to viral exposure. This action enables the immune system to manufacture virus-specific antibodies that are able to attack the virus when it enters the body. Vaccines have been instrumental in eliminating certain viral diseases such as smallpox and in offering a method for dealing with other viral infections and certain cancers. The development of new and more effective vaccines for various infectious and neoplastic diseases continues, and these agents will certainly be a welcome addition to the immunomodulatory drug armamentarium. Special Concerns for Rehabilitation Patients Physical therapists and occupational therapists are often involved in the rehabilitation of patients who have received heart, liver, kidney, and other organ transplants. Therapists also frequently deal with patients who have received autologous grafts, such as skin grafts for treating burns, and bone marrow transplants during the treatment of certain cancers. Therapists also deal with the rehabilitation of patients with musculoskeletal disorders that are caused by an autoimmune response. Patients with a compromised immune system may develop musculoskeletal problems related to their immunodeficient state. Hence, many patients receiving physical therapy and occupational therapy are frequently using immunomodulating drugs. Immunosuppressant drugs can have a positive impact on rehabilitation if they slow or arrest the progression of autoimmune diseases. Likewise, drugs that stimulate immune function will help prevent infections in patients who are immunocompromised, thereby enabling these patients to remain healthy enough to engage in exercise and other rehabilitation interventions. These drugs can also have a negative impact on rehabilitation because of their numerous side effects, especially those of the immunosuppressants. Many immunosuppressants, especially the glucocorticoids, exert catabolic effects on bone, muscle, and other tissues. Therefore, rehabilitation specialists can play a critical role in offsetting some of these adverse effects. Therapists can institute strengthening and general conditioning exercises to prevent breakdown of muscle, bone, and other tissues, as well as to maintain cardiovascular function. Thus, therapists can implement specific strategies as required to help patients cope with the adverse drug effects associated with immunomodulating agents. Kidney function was maintained artificially through renal dialysis until a suitable kidney transplant became available from a donor who died in an automobile accident. At the time of the transplant, cyclosporine was initiated at a dosage of 10 mg/kg of body weight each day. After 15 days, the dosage was decreased to 8 mg/kg per day and was progressively decreased over the next 2 months until a maintenance dosage of 4 mg/kg per day was achieved. Oral doses of methylprednisolone were then administered in dosages of 16 mg/d for the first 3 months, 12 mg/d for the next 3 months, and 8 mg/d thereafter. A loading dose of 6 mg of sirolimus (Rapamune) was administered orally after the transplant, and sirolimus was then maintained at a dosage of 2 mg per day throughout the posttransplant period. The therapist noted that several drugs were being used to prevent rejection, including rather high doses of methylprednisolone, a glucocorticoid agent. Immunosuppressants are a mainstay in preventing tissue rejection, and much of the current success of organ transplants is due to the judicious use of immunosuppressive drugs. These drugs are also beneficial in a number of diseases that have an autoimmune basis, and immunosuppressants can help alleviate symptoms or possibly even reverse the sequelae of certain diseases, such as rheumatoid arthritis. A few agents are also available that can augment or stimulate immune function in certain situations. The use of these immunostimulants will continue to expand as more is learned about how we can enhance the immune response in conditions such as cancer and certain immunocompromised states. However, immunomodulating drugs are not without problems, because many agents cause a rather nonspecific effect on immune function, which leads to serious side effects. As more is learned about the details of immune function, new drugs will be developed that are more selective in their ability to modify immune responses without causing a generalized suppression or activation of the immune system. From immunosuppression to immunomodulation: current principles and future strategies. Contributions of dendritic cells and macrophages to intestinal homeostasis and immune defense. A bioavailability study of cyclosporine: comparison of Neoral versus Cysporin in stable heart transplant recipients. Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation. New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation. Division of labor between lung dendritic cells and macrophages in the defense against pulmonary infections. Current pharmacotherapeutical options for the prevention of kidney transplant rejection. Current strategies and future trends in immunosuppression after heart transplantation. Oral cyclophosphamide is on the verge of extinction as therapy for severe autoimmune diseases (especially lupus): should nephrologists care Review article: strategies for the management of chronic unremitting ulcerative colitis. Mycophenolate mofetil as a rescue therapy for autoimmune hepatitis patients who are not responsive to standard therapy. Mycophenolate mofetil versus azathioprine as maintenance therapy for lupus nephritis: a meta-analysis. Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Long-term clinical outcomes following sirolimus-eluting stent implantation in patients with acute myocardial infarction. Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients. Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis. Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation. Use of tacrolimus and the development of posttransplant diabetes mellitus: a Brazilian single-center, observational study. Monoclonal antibodies and fusion proteins and their complications: targeting B cells in autoimmune diseases. Interleukin-2 receptor blockade with humanized monoclonal antibody for solid organ transplantation. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. An analysis of outcomes and treatment costs for children undergoing splenectomy for chronic immune thrombocytopenia purpura. Special considerations with the use of intravenous immunoglobulin in older persons. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. These substances often consist of natural products such as herbal preparations, vitamins, minerals, and other nutritional substances that consumers take to promote optimal health or to treat various conditions.

Secondary hypertension arthritis pain reliever mobic 7.5 mg order online, however symptoms of arthritis in feet and legs discount 15 mg mobic amex, accounts for less than 10 percent of the patients diagnosed with hypertension rheumatoid arthritis disease buy cheapest mobic and mobic. In essential hypertension arthritis symptoms in back or spine generic 7.5 mg mobic with visa, there is no clear arthritis in feet acupuncture order 7.5 mg mobic with amex, readily discernible cause of the elevated blood pressure. Consequently, the exact cause of hypertension in the majority of patients is unknown. Many theories have been proposed to explain how blood pressure increases and eventually becomes sustained in essential hypertension. The literature dealing with potential causes and mechanisms of essential hypertension is voluminous and cannot be reviewed extensively in this chapter. Possible Mechanisms in Essential Hypertension It appears there is a rather complex interaction of genetic and environmental factors that ultimately leads to adaptive changes in the cardiovascular system of patients with essential hypertension. These factors seem to be more influential in certain patients, suggesting a possible genetic predisposition to hypertension. Other risk factors such as cigarette smoking and alcohol abuse clearly play a role in potentiating the onset and maintenance of hypertension. Obesity is also an important risk factor for hypertension and various other types of cardiovascular disease. The exact way in which these factors interact probably varies from person to person, so the cause of this disease must be regarded individually rather than being based on one common etiology. Although the exact cause of hypertension is unknown, studies in humans and in animal models that mimic essential hypertension have suggested that the sympathetic nervous system may be a final common pathway in mediating and perpetuating the hypertensive state-that is, the factors described earlier may interact in such a way as to cause a general increase in sympathetic activity, which then becomes the common denominator underlying the elevated blood pressure in essential hypertension. Increased sympathetic drive may initially increase blood pressure by increasing cardiac output. In later stages, cardiac output often returns to normal levels, with the increased blood pressure being due to an increase in vascular resistance. The reasons for the shift from elevated cardiac output to elevated peripheral vascular resistance are somewhat unclear, but a sustained increase in sympathetic activity may be the initiating factor that begins a sequence of events ultimately resulting in essential hypertension. Once blood pressure becomes elevated, hypertension seems to become self-perpetuating to some extent. For example, mechanisms that control blood pressure (the baroreceptor reflex) may decrease in sensitivity, thus blunting the normal response to elevated pressure. Although the exact link between hypertension and metabolic syndrome is not clear, it is apparent that a chronic elevation in blood pressure is associated with metabolic impairments that further jeopardize the health of patients with this disease. Ultimately, certain environmental factors may turn on the sympathetic division of the autonomic nervous system in susceptible individuals. Increased sympathetic discharge then creates a vicious cycle whereby increased sympathetic effects-in conjunction with the increased blood pressure itself-help perpetuate hypertension. Various factors interact to turn on sympathetic outflow to the kidneys, heart, and peripheral vasculature, resulting in elevated blood pressure. Hypertension also causes structural and functional changes in the vasculature that help maintain the elevated pressure. Structural/functional change in heart and vasculature Increased blood pressure understood and may in fact vary from patient to patient. Hopefully future studies will elaborate on the exact role of factors causing essential hypertension, and treatment can then be focused on preventing the changes that initially increase blood pressure. These drugs are used as antihypertensive agents because of their ability to increase the renal excretion of water and sodium, thus decreasing the volume of fluid within the vascular system. This is somewhat analogous to the decrease in pressure that occurs inside a balloon when some of the air inside leaks out. Consequently, diuretics appear to have a rather direct effect on blood pressure through their ability to simply decrease the amount of fluid in the vascular system. The primary sites of action and effects of each category are summarized in Table 21-2. This section surveys the mechanism of action, rationale for use, specific agents, and adverse effects of drugs in each category. These drugs can be used alone or combined with other antihypertensives as needed to control hypertension in specific clinical situations (see "Drug Selection for Specific Patients With Hypertension"). Although they differ chemically, all diuretics exert their beneficial effects by acting directly on the kidneys to increase water and sodium excretion. The classifications include thiazide, loop, and potassium-sparing drugs (Table 21-3). These drugs act primarily on the early portion of the distal tubule of the nephron, where they inhibit sodium reabsorption. By inhibiting sodium reabsorption, more sodium is retained within the nephron, creating an osmotic force that also retains more water in the nephron. Because more sodium and water are passed through the nephron, where they will ultimately be excreted from the body, a diuretic effect is produced. These drugs act primarily on the ascending limb of the loop of Henle (hence the term loop diuretic). They exert their diuretic effect by inhibiting the reabsorption of sodium and chloride from the nephron, thereby preventing the reabsorption of the water that follows these electrolytes (see Table 21-3). The potassiumsparing diuretics are able to prevent the secretion of potassium into the distal tubule. Normally, a sodium-potassium exchange occurs in the distal tubule, where sodium is reabsorbed and potassium is secreted. Potassium-sparing agents interfere with this exchange in various ways (depending on the specific drug), and sodium remains in the tubule, where it is excreted. Although these agents do not produce a diuretic effect to the same extent as the loop and thiazide diuretics, potassium-sparing drugs have the advantage of reducing potassium loss and thus preventing hypokalemia (see Table 21-3). Adverse Effects the most serious side effects of diuretics are fluid depletion and electrolyte imbalance. Hence, diuretics should be used cautiously in patients who are prone to metabolic disorders, and concerns about metabolic side effects should be minimized by using the lowest possible dose. Orthostatic hypotension may occur because of the relative fluid depletion produced by these drugs. Sympatholytic Drugs As discussed previously, the preponderance of evidence indicates that an increase in sympathetic activity may be an underlying factor in essential hypertension. These sympatholytic drugs can be classified according to where and how they interrupt sympathetic activity. Sympatholytic drugs used to treat hypertension include beta-adrenergic blockers, alpha-adrenergic blockers, presynaptic adrenergic neurotransmitter depletors, centrally acting drugs, and ganglionic blockers (Table 21-4). Hypokalemia is a particular problem with the thiazide and loop diuretics but occurs less frequently when the potassium-sparing agents are used. Hypokalemia and other disturbances in fluid and electrolyte balance can produce serious metabolic and cardiac problems and may even prove fatal in some individuals. Consequently, patients must be monitored closely, and the drug dosage should be maintained at the lowest effective dose. A decrease in blood volume may cause a reflex increase in cardiac output and peripheral vascular resistance because of activation of the baroreceptor reflex (see Chapter 18). This occurrence may produce an excessive demand on the myocardium, especially in patients with cardiac disease. Decreased blood volume may also activate the renin-angiotensin system, thereby causing further peripheral vasoconstriction and increased cardiac workload. Again, the effects of fluid depletion may be especially serious in patients with certain types of heart failure. In hypertensive patients, these drugs lower blood pressure by slowing down the heart and reducing cardiac output. This is probably an oversimplification of how beta blockers produce an antihypertensive effect. In addition to their direct effect on the myocardium, beta blockers also produce a general decrease in sympathetic tone. Cardiovascular side effects include excessive depression of heart rate and myocardial contractility as well as orthostatic hypotension. Some of the traditional beta blockers may impair glucose and lipid metabolism, but this effect can be reduced by using one of the newer vasodilating beta blockers such as carvedilol. However, beta blockers are generally well tolerated by most patients, and the incidence of side effects is relatively low. The use of beta blockers in combination with these other agents is addressed in more detail in "Drug Selection for Specific Patients With Hypertension" later in this chapter. Beta-adrenergic blockers that are approved for use in hypertension are all effective in decreasing blood pressure (see Table 21-4), but certain beta blockers have additional properties that make them more suitable in specific patients. Beta blockers such as pindolol and acebutolol function as partial agonists and are said to Alpha Blockers Drugs that block the alpha-1­adrenergic receptor on vascular smooth muscle will promote a decrease in vascular resistance. In a sense, alpha blockers act directly on the tissues that ultimately mediate the increased blood pressure-that is, the peripheral vasculature. In the past, the use of alpha blockers in mild-to-moderate essential hypertension was somewhat limited because these drugs are sometimes too effective and tend to cause problems with hypotension and dizziness. They may produce a favorable effect on glucose metabolism and insulin resistance as well. Alpha-1 blockers can also be used to treat the symptoms of benign prostatic hypertrophy because they decrease sympathetic-mediated contraction of smooth muscle located in the prostate gland. Basically, these drugs can be differentiated according to their relative alpha-1 selectivity, their duration of action, and other pharmacokinetic properties. Prazosin (Minipress) has been the primary alpha blocker used in the past, but newer agents such as doxazosin and terazosin (Hytrin) are gaining acceptance in treating hypertension. Prazosin and other alpha blockers approved as antihypertensives are listed in Table 21-4. When peripheral vascular resistance falls due to the effects of these drugs, the baroreceptor reflex often responds by generating a compensatory increase in heart rate. This tachycardia may be a significant problem, especially if there is a history of cardiac disease. To prevent reflex tachycardia, a beta blocker may be administered with the alpha blocker. The beta blocker will negate the increase in heart rate normally mediated through the sympathetic innervation to the heart. Alternatively, use of a longeracting or controlled-release drug (doxazosin) may reduce the risk of reflex tachycardia because these agents produce a milder and more prolonged decrease in blood pressure following administration. Blockade of alpha-1 receptors in peripheral arteries and veins often promotes pooling of blood in the lower extremities when a patient stands up. Finally, there is concern that alpha blockers may increase the risk of cardiac disease, including congestive heart failure. Hence, alpha blockers should probably be avoided in patients at risk for heart failure and related cardiovascular problems. Likewise, alpha blockers may be a good choice for men with advanced hypertension and benign prostatic hypertrophy because these drugs may help resolve both problems simultaneously. Chapter 20 covers the drugs that inhibit the presynaptic synthesis and storage of norepinephrine. These agents have been available for several decades, but their use has declined over the years in favor of newer antihypertensives that are often better tolerated. Hence, reserpine is the only drug in this category that is still used commonly in the United States to treat hypertension (see Table 21-4). A slow heart rate (bradycardia) and other arrhythmias are sometimes a problem with reserpine. Ganglionic Blockers Drugs that block synaptic transmission at autonomic ganglia will dramatically and effectively reduce blood pressure by decreasing systemic sympathetic activity. Because of the effect of these agents on both divisions of the autonomic nervous system, ganglionic blockers are used sparingly in treating hypertension. In the past, these drugs were used to reduce blood pressure in hypertensive emergencies. Ganglionic blockers such as trimethaphan may be used to rapidly decrease blood pressure in certain emergencies, such as acute aortic dissection or autonomic crisis in people with spinal cord injury. As might be expected, ganglionic blockers produce a multitude of side effects because of the inhibition of both sympathetic and parasympathetic responses. Fortunately, ganglionic blockers are usually not used for extended periods because the patient is placed on other antihypertensive drugs when the hypertensive crisis is resolved. Centrally Acting Agents Several antihypertensives work by inhibiting sympathetic discharge from the brainstem (see Table 21-4). Sympathetic discharge from the vasomotor center appears to be influenced by two types of neuronal receptors located in the brainstem: alpha-2 adrenergic receptors and imidazoline type I1 receptors. Stimulation of these receptors results in a decrease in sympathetic discharge to the heart and vasculature. Centrally acting sympatholytics are therefore characterized as agonists for either one or possibly both types of these receptors. Clonidine, for example, is considered to be primarily an alpha-2 agonist, although this drug also has some ability to stimulate imidazoline receptors. Of the primary drugs in this category, clonidine, guanabenz, and guanfacine act directly on the alpha-2 receptor, whereas methyldopa acts as an alpha-2 agonist after being converted in vivo to alpha-methylnorepinephrine. At therapeutic doses, these drugs are associated with some troublesome but relatively minor side effects, including dry mouth, dizziness, and sedation. Hence, agents that are more selective for imidazoline receptors may seem better tolerated because patients are more alert and have less psychomotor slowing. These drugs are not usually the first medications used in patients with hypertension but tend to be added to the drug regimen if other agents. As indicated earlier, hypertension may be perpetuated by a defect in the production of nitric oxide by the vascular endothelium.

Second malignancies developed in 2153 patients (7%) which rheumatoid arthritis jaw joint order genuine mobic line, compared to the age- and sex-adjusted general population enteropathic arthritis definition order mobic in india, was an increase of more than a factor of 2 arthritis in neck and tmj purchase mobic paypal. The risk of late-developing solid cancers was particularly increased after radiotherapy while second leukaemias were mostly related to chemotherapy arthritis today diet mobic 7.5 mg purchase visa. The highest absolute excess second cancer risk was for cancers of the lung and breast equate arthritis pain gluten free order mobic australia. The authors calculated a 25-year cumulative risk of treatment-induced second cancers of 11. In their review of late effects after treatment for Hodgkin lymphoma, Swerdlow and van Leeuwen [18] concluded that the substantial increase in solid tumour risk with time since diagnosis necessitated careful, lifelong medical surveillance of all patients. In particular, women treated with mantle field irradiation before the age of 30 are at greatly increased risk of breast cancer and follow-up of these women should include yearly mammography; however, the efficacy of these measures has not yet been demonstrated. The most important message of the prostate cancer study is that half of all radiation-induced second cancers occur in the high-dose organs (bladder, rectum) and the other half in the organs exposed to low doses (lung). It is likely that different mechanisms are involved in the high- and low-dose organs. The mechanisms of low-dose radiation carcinogenesis have been explored in radiation protection research [13]. On the other hand, high radiation doses may lead to chronic radiation injury characterized by microvascular damage, parenchymal atrophy and chronic inflammation, a typical pre-cancerous lesion. Breast cancer Patients treated with post-operative radiotherapy for breast cancer receive significant radiation doses of more than 5% of the target dose to the contralateral breast. Since second cancers in the contralateral breast occur more frequently than expected and comprise nearly half of all second cancers in women with breast cancer, a causal relationship with the radiation exposure from the treatment of the first cancer was suggested. It is particularly in young breast cancer patients that the dose to the contralateral breast should be carefully controlled. Patients treated with post-operative radiotherapy for breast cancer receive very different doses to the ipsilateral compared to the contralateral lungs. Twenty-five years after treatment of the primary malignancy, the cumulative risk was 5%; five years later it approached 8%. In 543 patients who had already attained an age >30 years, 16 second cancers were diagnosed while only 3. In a study on 102 second cancers among 930 children treated for Hodgkin disease, Constine et al. This is mainly due to the high rate of cancers of the breast, but also of thyroid carcinomas and of sarcomas in females. These three cancer types comprise three-quarters of all second cancers in female Hodgkin survivors. Second cancers after childhood cancer radiotherapy are a particularly serious problem in female patients. The 2007 Recommendations of the International Commission on Radiological Protection. Dose-effect relationships and estimation of the carcinogenic effects of low doses of ionising radiation. The joint report of the Académie des Sciences (Paris) and of the Académie Nationale de Médecine. International Journal of Radiation Oncology* Biology* Physics 2005; 63(2): 317­319. Mortality from cancer and other causes after radiotherapy for ankylosing spondylitis. Increased lung cancer risk due to residential radon in a pooled and extended analysis of studies in Germany. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Of these 60,271 (9%) developed a second solid cancer between five and 12 years after treatment of the first cancer. The relative risk of second cancer and the proportion of cancers attributable to radiotherapy were calculated by comparing cancer rates for patients receiving radiotherapy versus patients not receiving radiotherapy in the definitive treatment of 15 types of first malignancy. In total, an estimated 3266 excess solid cancers could be related to radiotherapy in these five-year survivors, i. The authors estimated that for every 1000 patients treated with radiotherapy there were an estimated three excess cancers by ten years after first cancer diagnosis which increased to five excess cases by 15 years. The risk of radiation-induced second cancers is much greater in young and very young cancer patients. All estimates of treatment-related second cancers made above are inevitably based on retrospective analyses of results from treating patients many years ago, yet the situation has changed dramatically in radiation oncology during the last two decades. In particular, studies in patients treated as children with chemotherapy plus radiotherapy demonstrated that both treatment modalities increase the risk of secondary malignancy in cured patients, both regarding leukaemias and solid cancers. Second malignant neoplasms after a first cancer in childhood: temporal pattern of risk according to type of treatment. Frequency distribution of second solid cancer locations in relation to the irradiatred volume among 115 patients treated for childhood cancer. Radiation therapy and late mortality from second sarcoma, carcinoma and hematological malignancies after a solid cancer in childhood. International Journal of Radiation Oncology * Biology * Physics 2011; 80: 339­346. International Journal of Radiation Oncology* Biology* Physics 2008; 71: 1021­1030. Second primary cancers after adjuvant radiotherapy in early breast cancer patients: A national population based study under the Danish Breast Cancer Cooperative Group. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. Among men in more developed regions, prostate cancer is most common, followed by lung and colorectal cancer [1]. Among men in less developed regions, lung cancer is most prominent, followed by stomach and liver cancer. Among women, breast cancer is the most frequently occurring form of cancer in developed regions of the world, followed by cancer of the colorectum and the lung. In less developed regions, breast cancer is also the most common type of cancer among women, followed by cervix uteri, lung, and stomach cancer. Migrant studies, in which people moved from one part of the world to another, have shown that cancer rates among these populations change rapidly over generations and become comparable to the cancer rates of the host country [2­6]. These observations indicate that in addition to genes, lifestyle, including diet and physical activity, is important in the aetiology of cancer. In 1981, Doll and Peto estimated that about 35% of all cancer deaths are attributable to dietary habits [7]. This report was built on evidence from their second expert report Food, Nutrition, Physical Activity and the Prevention of Cancer: A Global Perspective [9]. In addition to the influence of lifestyle factors on the occurrence of cancer later in life, the second expert report also acknowledged that research on lifestyle factors during and after cancer is important, because the number of people that are diagnosed with cancer as well as those who survive cancer is increasing. This chapter describes the evidence on the role of body fatness, physical activity, diet, and other lifestyle factors1 in the aetiology as well as the progression of cancer, it discusses what proportion of cancer cases is attributable to these factors, and it provides evidence-based recommendations for the general public. Development of cancer Body fatness As greater body fatness strongly and consistently increases the risk of many types of cancer, it is one of the most important risk factors for cancer as a whole. The evidence that it causes cancer of the breast (after menopause), colorectum, pancreas, oesophagus (only adenocarcinomas), endometrium, and kidney is convincing, whereas it is probable for gallbladder cancer [9­11]. In contrast, greater body fatness probably protects against breast cancer before menopause. It is not only the amount of fat tissue, but also the location of fat tissue within the body that is important in the development of cancer. Greater abdominal (central) fatness is convincingly associated with an increased risk of colorectal cancer and it probably also causes breast cancer (after menopause), pancreatic cancer, and endometrial cancer [9­11]. The mechanism behind these associations is thought to run via increased circulating concentrations of hormones and growth factors, such as sex hormones, insulin, and insulin-like growth factor, which are involved in carcinogenesis [12, 13]. In addition, body fatness is characterized by elevated levels of pro-inflammatory factors, which can promote cancer development [12, 13]. Although estimates of population attributable fractions vary between studies according to the methodology used, the number of cancer cases that are attributable to body fatness also differ by type of cancer and by population (Table 18. A healthy weight is best achieved by choosing diets based on foods with low-energy density, avoiding sugary drinks, and being physically active throughout life. In addition to the beneficial effect of physical activity on body fatness, this may be due to its favourable influence on endogenous steroid hormone metabolism and immune function [16]. This means building regular moderate, and some vigorous physical activity into everyday life, and diminishing the time spent sitting. Diet Plant foods In general, plant foods are assumed to protect against cancer, as most diets that decrease the risk of cancer mainly contain foods of plant origin. The observed inverse associations between plant foods separately and the development of cancer, however, are relatively weak and are still debated [17]. The evidence that has currently been established is the following: a relatively high consumption of non-starchy vegetables, which includes green, leafy vegetables, cruciferous vegetables, and allium vegetables, probably protects against cancer of the upper-gastrointestinal tract (mouth, pharynx, larynx, oesophagus, and stomach) [9]. Allium vegetables alone probably also protect against stomach cancer, whereas garlic specifically has been shown to decrease the risk of colorectal cancer [9, 11]. Foods containing dietary fibre, which also includes vegetables and fruits, is convincingly protective against colorectal cancer [11, 18]. In addition to dietary fibre, the beneficial effects of vegetables and fruits may be due to specific vitamins or other bioactive compounds, such as carotenoids including beta-carotene and lycopene (coloured vegetables), folates (green leafy vegetables and brassica), glucosinolates (brassica), and allyl sulphides (garlic and onions). Non-starchy vegetables and fruits are also typically low in energy density; thus a diet high in these products probably also protects against weight gain. In addition, they both promote the consumption of unprocessed cereals (whole grains) and limit the consumption of refined grain products. On the other hand, diets high in calcium are probably associated with an increased risk of prostate cancer. Based on these findings, it may be hypothesized that calcium both has an inhibiting as well as a promoting role in the carcinogenic process, which may differ by cell type. Calcium may reduce colorectal carcinogenesis by binding to secondary bile acids and fatty acids, which prevents them from exerting their proliferative effects on colonic epithelial cells. In addition, calcium may directly influence the colorectal carcinogenic process by inducing differentiation in normal cells and apoptosis in transformed cells [9]. The mechanism of calcium in prostate carcinogenesis is proposed to involve vitamin D. A high intake of calcium down-regulates the formation of 1,25 dihydroxyvitamin D, which may result in increased cell proliferation in the prostate [9]. Due to these conflicting results, the proportion of cancers that can be prevented by drinking or not drinking milk cannot be determined and no recommendations are provided. A high consumption of alcoholic drinks is convincingly associated with cancer of the mouth, pharynx, larynx, oesophagus, and breast (before and after menopause). It is also convincingly a cause of colorectal cancer in men, whereas it is probably a cause for colorectal cancer in women, and for liver cancer [9]. It is not the type of alcohol drink that is consumed that is important but the total intake of ethanol. The primary metabolite of ethanol, acetaldehyde, as well as other reactive metabolites, may be carcinogenic. In addition, alcohol may influence the production of prostaglandins, lipid peroxidation, and the generation of free-radical oxygen species. If only the evidence on cancer was taken into account, all amounts of alcohol should be avoided. Animal foods Animal foods typically include meat, poultry, fish, eggs, as well as milk and other dairy products. The evidence for most of these foods in relation to the development of cancer is limited, with the exception of meat and milk. Red meat, which includes beef, pork, lamb, and goat, as well as processed meat, meaning meats that are preserved by smoking, curing, salting, or the addition of chemical preservatives. The exact mechanism by which red and processed meat increases colorectal cancer risk is unclear [11]. Factors that may play a role in colorectal carcinogenesis are specific mutagens, such as heterocyclic amines and polycyclic aromatic hydrocarbons, which are formed when meat is cooked well done at a very high temperature or over a direct flame. A specific component in red meat that may also be involved in the carcinogenic process is heme iron. This compound, which gives meat its red colour, may act through two different pathways: (1) it catalyses the peroxidation of fat in the gastrointestinal tract, which produces cytotoxic and mutagenic alkenals; (2) it induces the production of carcinogenic N-nitroso-compounds in the gastrointestinal tract. These latter N-nitroso-compounds can also be formed when nitrates and nitrites are added as preservatives to processed meats during the curing process. Although the evidence on milk and the development of cancer is not limited, it is conflicting [9]. On the one hand, the consumption of milk probably protects against cancer of the colon and rectum, which is thought to occur at least in part due to a higher Preservation, processing, and preparation of foods Some methods of food preservation, processing, and preparation may affect cancer risk. It is the overall amount of salt that is consumed in itself and with salt-preserved foods that probably causes stomach cancer. Aflatoxins are produced by some moulds when the above-mentioned foods are stored too long in warm temperatures. Since there is hardly any consistent scientific evidence available, the current recommendation for patients who have finished treatment is to aim to follow the guidelines to prevent cancer [9]: achieve and maintain a healthy weight, engage in regular physical activity, and adopt a healthy diet [9, 22]. Other lifestyle factors Dietary supplements the findings for dietary supplements in the development of cancer are inconsistent [9]. Some studies have observed decreased risks for certain types of cancer, while others did not find any association or even reported an increased risk for particular forms of cancer.

Additional information:

• Albendazole
• Enalapril-hydrochlorothiazide
• Indapamide

References

• Roukoz H, Bavry AA, Sarkees ML, et al. Comprehensive meta-analysis on drugeluting stents versus bare-metal stents during extended follow-up. Am J Med. 2009;122:581.
• Yuh WT, Nguyen HD, Gao F, et al. Brain parenchymal infection in bone marrow transplantation patients: CT and MR findings. AJR Am J Roentgenol. 1994;162(2):425-430.
• Kaley T, Barani I, Chamberlain M, et al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol 2014; 16(6):829-840.
• Zaja F, Bacigalupo A, Patriarca F, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 2007;40(3):273-277.
• Grayhack JT, McCullough W, OiConor VJ Jr, et al: Venous bypass to control priapism, Invest Urol 1:509n513, 1964.
• El-Serag HB, Aguirre TV, Davis S, et al: Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's. Am J Gastroenterol 99:1877, 2004.
• In: McMahon SB, Koltzenburg M, eds. Wall and Melzack's Texbook of Pain. Philadelphia: Elsevier; 2006:125-142.
• Kabalin JN: Addition of a second urethral cuff to enhance performance of the artificial urinary sphincter, J Urol 156:1302n1304, 1996.